Evidence map›Paper›PMID 33374459›Full record

ReviewInternational journal of molecular sciences2020

Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements.

Ahmed Malki, Rasha Abu ElRuz, Ishita Gupta, Asma Allouch, Semir Vranic, Ala-Eddin Al Moustafa

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 1 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 1 synthesis or guideline pooled it, 377 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. BRAFJournal of experimental & clinical cancer research : CR · 2026
    Article

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ahmed MalkiDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha 2713, Qatar.
Rasha Abu ElRuzDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha 2713, Qatar.
Ishita GuptaCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.ORCID 0000-0002-8627-3186
Asma AllouchDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha 2713, Qatar.
Semir VranicCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.
Ala-Eddin Al MoustafaCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.ORCID 0000-0003-4452-3439
Qatar University · QA

Funding

Qatar University QUHI-CMED-19/20-1 and QUCG-CMED-20/21-2
6 · The paper itself

Abstract

Colorectal cancer (CRC), the third most common type of cancer, is the second leading cause of cancer-related mortality rates worldwide. Although modern research was able to shed light on the pathogenesis of CRC and provide enhanced screening strategies, the prevalence of CRC is still on the rise. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, analyzing signaling pathways involved in CRC metastasis is necessary to elucidate the underlying mechanism of CRC progression and pharmacotherapy. This review focused on target genes as well as various cellular signaling pathways including Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF, and JAKs/STAT3, which are associated with CRC progression and metastasis. Additionally, alternations in methylation patterns in relation with signaling pathways involved in regulating various cellular mechanisms such as cell cycle, transcription, apoptosis, and angiogenesis as well as invasion and metastasis were also reviewed. To date, understanding the genomic and epigenomic instability has identified candidate biomarkers that are validated for routine clinical use in CRC management. Nevertheless, better understanding of the onset and progression of CRC can aid in the development of early detection molecular markers and risk stratification methods to improve the clinical care of CRC patients.

Indexed as

Disease ProgressionGene Expression Regulation, NeoplasticNeoplasm MetastasisAdenomatous Polyposis Coli ProteinAnimalsbeta CateninCell MovementChromosomal InstabilityChromosomes, Human, Pair 18ColonColorectal NeoplasmsCpG IslandsErbB ReceptorsGene Expression ProfilingHumansLoss of HeterozygosityAdenomatous Polyposis Coli ProteinAPC protein, humanbeta CateninBRAF protein, humanCTNNB1 protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53Wnt Proteinschromosomal instabilityColorectal cancermicrosatellite instabilitymolecular pathwaystherapeutics

Identifiers

PMID33374459
PMCPMC7794761
OpenAlexW3117886022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.